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Objective: A meta-analysis was conducted to determine the influ-
ence of gender, race, and marital status on overall survival (OS) in
Radiation Therapy Oncology Group nonoperative non-small cell
lung cancer trials.
Materials and Methods: Data from 1365 patients treated on nine
prospective Radiation Therapy Oncology Group studies activated
during the 1990s were analyzed. Impact of gender, marital status,
and race was considered in the Cox proportional hazards models.
Age, Karnofsky performance status, weight loss, stage, histology,
location of primary tumor, biologic equivalent dose, deviation from
protocol dose, and education level were adjusted in the model. A
two-sided p value 0.05 was considered statistically significant.
Results: Males had significantly higher mortality than females
adjusted for other covariates (hazard ratio [HR]  1.22, 95%
confidence interval  1.08–1.38). Race and marital status were not
independently predictive for OS. Single females had significantly
better OS than single males (HR  0.72), and married males had
lower OS than single females (HR  1.36).
Conclusions: These results suggest that although certain subgroups
of gender, race, and/or marital status have better outcomes with
respect to OS; gender seems to be the most significant factor
influencing survival results among nonoperative non-small cell lung
cancer patients.
Key Words: Sociodemographic factors, Survival, Non-small cell
lung cancer.
(J Thorac Oncol. 2010;5: 631–639)
Lung cancer is a major global health concern; an estimated1.35 million new cases were reported in 2002 resulting in
1.18 million deaths.1 In the United States, it is estimated that
215,020 cases occurred in 2008 (with 114,690 cases in men
and 100,330 in women), resulting in a total of 161,840
deaths.2 Lung cancer deaths exceed the total number of
deaths due to the two next most cancers in both men (pros-
tate, colorectal) and women (breast, colorectal) combined.
Lung cancer surpassed breast cancer as the leading
cause of cancer death in women in 1987.3 This is primarily
attributable to cigarette smoking, which gained cultural ac-
ceptance among women around World War II and peaked in
the 1960s and has only gradually declined since then. A 15-
to 20-year latency period is reflected in the progressive
increase in lung cancer deaths in women from 2.5/100,000 in
1930s to 5/100,000 in the 1960s to 40/100,000 in 2000.3,4 A
convergence in lung cancer rates between males and females
has also been noted with the minimum ratio being 1.1 for
people born around 1970. This is substantially reduced com-
pared with a ratio of seven males to one female for individ-
uals born in the 1910s.5 According to the Centers for Disease
Control, 22.4% of women in the reproductive age group of 18
to 44 years continue to smoke.6
Active investigation into the prognostic factors predict-
ing outcome for lung cancer patients has established stage,
performance status, and weight loss as the three most impor-
tant factors.7 In a recent analysis, Sculier et al.8 studied more
than 12,000 patients with non-small cell lung cancer
(NSCLC) in the International Association for the Study of
Lung Cancer database. The results show that stage, perfor-
mance status, age, and gender significantly predicted sur-
vival. Social factors have also been noted to be important
prognostic factors for other cancers. For example, in a study
of patients enrolled in three Radiation Therapy Oncology
Group (RTOG) head and neck cancer trials, men without
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partners had a statistically significant survival disadvantage9
compared with partnered men and to women, regardless of
partnership status.
Based on these results, further investigation and re-
search on gender, marital status, and racial differences in
incidence and outcome in patients with lung cancer needs to
be performed. The influence of sociodemographic factors
including gender, race, and marital status on overall and
disease-free survival was examined using data from patients
treated on nine prospective RTOG nonoperative NSCLC trials.
PATIENTS AND METHODS
Patients
Patients enrolled in nine RTOG trials were included
in this analysis—RTOG 9015, 9103, 9106, 9204, 9205,
9304 (radiation therapy [RT] arm only), 9311, 9410, and
9801. A brief description of these trials follows: RTOG
9015, phase I/II concurrent chemotherapy (CRT) and hy-
perfractionated (HFX) RT; 9103, pulmonary function of
patients with RT; 9106, phase I/II—HFX RT and CRT;
TABLE 1. Pretreatment Characteristics by Studies
RTOG Study
9015
(n  23)
9103
(n  106)
9106
(n  73)
9204 Arm 1
(n  74)
9204 Arm 2
(n  78)
9205
(n  34)
Age
Mean 65.3 65.0 59.9 60.2 59.4 65.8
Range 50–78 38–86 31–80 39–79 42–79 43–83
Median 66 65 62 61.5 59 67
Gender (%)
Male 19 (83) 64 (60) 45 (62) 54 (73) 44 (56) 26 (76)
Female 4 (17) 42 (40) 28 (38) 20 (27) 34 (44) 8 (24)
Race (%)
White 21 (91) 75 (71) 65 (89) 66 (89) 63 (81) 32 (94)
Non-White 2 (9) 31 (29) 8 (11) 8 (11) 15 (19) 2 (6)
Marital status (%)
Married/other live-in relationship 14 (61) 72 (68) 52 (71) 58 (78) 61 (78) 19 (56)
Single/divorced/separated/widowed 9 (39) 34 (32) 21 (29) 16 (22) 17 (22) 15 (44)
KPS (%)
60–80 8 (35) 54 (51) 16 (22) 19 (26) 18 (23) 22 (65)
90–100 15 (65) 52 (49) 57 (78) 55 (74) 60 (77) 12 (35)
Stage (%)a
I–II 0 (0) 9 (8) 4 (5) 1 (1) 1 (1) 3 (9)
IIIA 7 (30) 55 (52) 27 (37) 25 (34) 26 (33) 13 (38)
IIIB 16 (70) 42 (40) 42 (58) 48 (65) 51 (65) 18 (53)
Histology (%)
Nonsquamous 12 (52) 40 (38) 42 (58) 41 (55) 45 (58) 20 (59)
Squamous 11 (48) 66 (62) 31 (42) 33 (45) 33 (42) 14 (41)
Lobar location (%)
Lower lobes 2 (9) 17 (16) 10 (14) 5 (7) 14 (18) 0 (0)
All Other 21 (91) 89 (84) 63 (86) 69 (93) 64 (82) 34 (100)
BEDb
Mean 67.1 71.6 72.2 73.4 74.3 85.5
Range 16.1–79.8 19.2–81.6 21.5–81.1 23.4–81.7 29.6–81.7 23.1–93.4
Median 78 72 78 74.7 78 87.9
Deviations of total dose received from
total dose in protocol (%)
Actual total dose is 95% 6 (26) 11 (10) 12 (16) 5 (7) 13 (17) 2 (6)
Actual total dose is 95–110% 17 (74) 95 (90) 61 (84) 69 (93) 65 (83) 32 (94)
Highest education levelb (%)
High school/GED 8 (35) 25 (24) 27 (37) 13 (18) 15 (19) 14 (41)
High school/GED 7 (30) 36 (34) 20 (27) 26 (35) 34 (44) 11 (32)
College/technical 7 (30) 13 (12) 25 (34) 29 (39) 21 (27) 6 (18)
Prefers not to answer 0 4 (4) 1 (1) 6 (8) 7 (9) 3 (9)
Missing 1 (4) 1 (1) 0 0 (0) 1 (1) 0
a Maximum of clinical and pathologic stage group.
b Based on actual dose per fraction (Gy).
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9204, phase II randomized—CRT/RT for NSCLC; 9205,
phase II nonrandomized—thrice a day RT to 79.2 Gy;
9304, phase III conventional therapy with or without
recombinant -interferon for patients with locally ad-
vanced NSCLC; 9311, phase I/II dose escalation study
using three-dimensional conformal RT in patients with
inoperable NSCLC; 9410, three-arm phase III study of
concomitant versus sequential CRT and thoracic RT for
patients with locally advanced inoperable NSCLC; and
9801, phase III study of amifostine for mucosal protection
for patients with favorable prognosis inoperable stage II to
IIIA/B NSCLC receiving sequential induction and concur-
rent HFX RT with paclitaxel and carboplatin.
All patients received either RT alone or RT and CRT as
a part of their treatment. There was no surgical arm in any of
the trials. The period of accrual for was from 1991 to 2002.
Pretreatment and demographic information was obtained at
registration for each trial.
TABLE 1. Continued
9304
(n  55)a
9311
(n  162)a
9410 Arm 1
(n  170)a
9410 Arm 2
(n  184)a
9410 Arm 3
(n  183)a
9801
(n  223)a
Total
(n  1365)
65.0 70.6 61 59.9 60.8 61.1 62.4
43–82 37–92 33–78 33–79 35–80 34–81 31–92
67 72 62 60 63 62 64
32 (58) 86 (53) 103 (61) 118 (64) 122 (67) 139 (62) 852 (62)
23 (42) 76 (47) 67 (39) 66 (36) 61 (33) 84 (38) 513 (38)
47 (85) 143 (88) 147 (86) 161 (88) 157 (86) 187 (84) 1164 (85)
8 (15) 19 (12) 23 (14) 23 (13) 26 (14) 36 (16) 201 (15)
31 (56) 94 (58) 128 (75) 129 (70) 129 (70) 164 (74) 951 (70)
24 (44) 68 (42) 42 (25) 55 (30) 54 (30) 59 (26) 414 (30)
41 (75) 103 (64) 40 (24) 44 (24) 45 (25) 54 (24) 464 (34)
14 (25) 59 (36) 130 (76) 140 (76) 138 (75) 169 (76) 901 (66)
0 (0) 84 (52) 3 (2) 3 (2) 4 (2) 14 (6) 126 (9)
25 (45) 50 (31) 73 (43) 77 (42) 73 (40) 106 (48) 557 (41)
30 (56) 28 (17) 94 (55) 104 (57) 106 (58) 103 (46) 682 (50)
25 (45) 91 (56) 106 (62) 111 (60) 107 (58) 148 (66) 788 (58)
30 (55) 71 (44) 64 (38) 73 (40) 76 (42) 75 (34) 577 (42)
7 (13) 43 (27) 31 (18) 26 (14) 31 (17) 46 (21) 232 (17)
48 (87) 119 (73) 139 (82) 158 (86) 152 (83) 177 (79) 1133 (83)
68.2 93.7 73.8 73.1 74.2 76 76.2
4.7–72.4 13.1–114.3 42.5–77.1 14.9–77.8 1.3–82.3 17.5–85.6 1.3–114.3
72 94 74.7 74.7 78 78 77.7
5 (9) 13 (8) 10 (6) 9 (5) 25 (14) 27 (12) 138 (10)
50 (91) 149 (92) 160 (94) 175 (95) 158 (86) 196 (88) 1227 (90)
22 (40) 53 (33) 39 (23) 53 (29) 46 (25) 48 (22) 399 (29)
14 (25) 52 (32) 62 (36) 62 (34) 57 (31) 89 (40) 461 (34)
15 (27) 45 (28) 60 (35) 63 (34) 72 (29) 76 (34) 432 (32)
3 (5) 10 (6) 7 (4) 2 (1) 6 (3) 6 (3) 55 (4)
1 (2) 2 (1) 2 (1) 4 (2) 2 (1) 4 (2) 18 (1)
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Statistical Methods
A 2 test was applied to evaluate the homogeneity of
the data and to establish whether one estimate could be used
to represent the metadata from nine different trials. To take
into account, the differences among the trials such as the
patient population, treatment, and the period of accrual, the
metadata were stratified by the trial or treatment arms (strat-
ification variable [STR]). Hazard ratio (HR) was used as an
estimator for time to event outcome. The pooled HR estima-
tor10,11 with weight of the inverse of variance of estimator
were used. If there was homogeneity among the trials or
treatment arms, the pooled HRs would be used as the esti-
mator for the combined data.
The 2 test statistics, t test statistics, or Fisher’s exact
test were used to determine whether there was a difference
with respect to the pretreatment characteristics and out-
comes of patients with and without missing data. These
test statistics were also used to compare the pretreatment
characteristics of patients.
Outcomes for this study included overall survival
(OS), where failure was defined as death due to any cause.
The following covariates were considered in the two out-
comes in the models: race (white [reference level {RL}]
vs. Non-white), gender (female [RL] vs. male), and marital
status (married/other live-in relationship [partnered] [RL]
vs. single/divorced/separated/widowed [single]).
The other covariates considered for OS in addition to
race, gender, and marital status were age (continuous), KPS
(60–80 [RL] vs. 90–100), weight loss in last 3 months (5%
[RL] vs.5%), histology (nonsquamous [RL] vs. squamous),
stage (I–II [RL] vs. IIIA vs. IIIB), lobar location (all other
[RL] vs. Lower lobes), BED based on actual dose per fraction
(continuous), deviations of total dose received from total dose
in protocol (95% [RL] vs. 95%), and highest education
level (high school/GED [RL] vs. high school/GED vs.
college/technical school). The Kaplan-Meier method was
used to estimate the survival rate.12
The metadata were stratified by trials with the excep-
tion of RTOG 9204 and RTOG 9410, because the treatments
were too different. These two trials were divided by treatment
arms. This resulted in 12 stratification variables (STR) among
the nine included trials.
Stratified Cox proportional hazard models (by trial or
treatment arms) were used to assess the gender, marital status,
and race effect with and without adjusting for the other
covariates listed earlier.13 Unadjusted and adjusted HRs were
calculated for all covariates using the stratified Cox propor-
tional hazards model with associated 95% confidence inter-
vals (CIs). All statistical tests were two-sided, and a p  0.05
was considered statistically significant. Statistical Analysis
System (SAS Institute, Cary, NC) was used for all statistical
analyses.
RESULTS
The analyzable number of patients from the nine RTOG
trials (12 STR) with radiation dose information available was
1433. Sixty-eight (5%) patients were excluded because of
missing or unknown marital status; hence, 1365 patients were
included in this analysis. Table 1 lists the pretreatment char-
acteristics of patients from nine trials by STR. Sixty-two
percentage (852) of these patients were male, 85% (1164)
were white, and 70% (951) were married or in a live-in
relationship. Seven hundred seven (52%) were white males,
and 145 (11%) nonwhite males. There were statistically
significant differences with respect to highest education level
(p  0.0001), and stage (p  0.0326) between the patients
without (n  1365) and with (n  68) missing data (the
results are not shown).
Heterogeneity testing was performed for the metadata
as described in the Patients and Methods section. These
results are shown in Table 2. The 12 STR from nine trials
were found to be homogeneous with respect to the HRs of OS
with respect to gender, marital status, and race, so the pooled
HRs could be used (p values for 2 TS 0.1). A statistically
significant decrease in OS was noted for males (pooled HR
1.24; 95% CI 1.09–1.41). No statistically significant effect
of marital status or race on OS was noted.
Cox proportional hazard regression models were per-
formed by STR. A statistically significant decrease in OS for
males (pooled adjusted HR1.22; 95% CI 1.08–1.38) was
noted, whereas no difference was seen for marital status or
race. The interactions among gender, marital status, and race
were investigated without adjusting other covariates. There
were no statistically significant interactions (all the 95% CIs
includes 1) predicting for OS.
The summary of subgroups by gender, marital status,
and race are shown in Table 3. Single white males had the
lowest 2-year OS estimates (26% [95% CI  19%, 33%])
whereas married white females had a higher survival rate (40%
[95% CI  34%, 46%]). The numbers of single nonwhite
females and males are too small to make any meaningful
conclusion. Single females, married females, white females, and
non-white females had higher OS rates than other subgroups.
The results of comparisons of subgroups are shown in
Table 4. Subgroup analysis revealed that single white males
had statistically significant inferior OS than single white
females (adjusted HR  1.49, 95% CI  1.17–1.91). Single
females also had statistically significantly better OS outcomes
compared with single males (adjusted HR  0.72, 95% CI 
0.58–0.89). Married males had a significantly inferior OS
compared with single females (adjusted HR  1.36, 95%
CI  1.14–1.62). White females had better OS outcomes
compared with white males (adjusted HR  0.80, 95% CI 
0.70–0.92). The numbers of patients in the non-white mar-
ried and non-white single cohorts are too small to draw a
meaningful conclusion.
DISCUSSION
We examined the role of sociodemographic factors
influencing outcome in patients with inoperable NSCLC.
Pooled prospective data on more then 1300 patients enrolled
in nine RTOG trials were used for this analysis. The results
indicated that the only factor significantly affecting outcome
was gender, with women having better OS. Marital status and
race did not significantly predict outcome. Weight loss, age,
KPS, lobar location, BED, dose, and education were all
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variables that were statistically significantly (P  0.05)
associated with outcome. However, details have not been
presented as these were not variables of interest for our
analysis.
The role of gender as a prognostic factor in lung cancer
has been studied previously. Most analyses suggest that
women have more favorable outcomes14–23; however, occa-
sional evidence to the contrary exists24–26 (Table 5). Interest-
ingly, the incidence of grade 3 and 4 treatment-related tox-
icities are higher in women. This has been observed in
patients enrolled in CRT trials22,24,27,28 and chemoradiation
trials for lung cancer.29
Gender differences in response to treatment are most
evident regarding tyrosine kinase inhibitors targeting the
epidermal growth factor receptor (EGFR). Approximately
10% of the patients have a rapid clinical response to this
agent. Lynch et al.30 were able to identify mutations in the
EGFR gene, which conferred dramatic sensitivity to gefitinib.
These mutations are more commonly seen in women, espe-
cially of Asian origin, and in nonsmokers.31 Estrogen recep-
tor (ER)- expression, which is associated with improved
survival, is observed significantly more frequently in female
patients.32 Reduced levels of p-glycoprotein in females pro-
long drug half-life of vinca alkaloids, doxorubicin, etoposide,
and docetaxel.33 This may partly explain the greater drug-
related toxicity and better response in women. Defective
DNA repair observed in women with NSCLC may lead to
improved outcome in patients treated with cisplatin-based
CRT.34 Gender-dependent dosing of chemotherapeutic agents
may yield therapeutic gains; and this issue requires further
investigation.
There has been extensive research into the molecular
and biologic factors that may contribute to gender differences
TABLE 3. Summary of Subgroup for Overall Survival
Failure by
2 yr
2-yr Overall Survival
Estimates (95% CI)
Marital status, race, gender (n)
Married,a white, female (n  279) 166 0.40 (0.34–0.46)
Married, white, male (n  554) 366 0.33 (0.29–0.37)
Single, white, female (n  178) 107 0.39 (0.32–0.47)
Single, white, male (n  153) 112 0.26 (0.19–0.33)
Married, non-white, female (n  24) 15 0.35 (0.16–0.55)
Married, non-white, male (n  94) 64 0.31 (0.22–0.41)
Single, non-white, female (n  32) 19 0.41 (0.24–0.58)
Single, non-white, male (n  51) 31 0.39 (0.26–0.53)
Gender, marital status
Female, married (n  303) 181 0.40 (0.35–0.45)
Male, single (n  204) 143 0.29 (0.23–0.35)
Male, married (n  648) 430 0.33 (0.20–0.37)
Female, single (n  210) 126 0.40 (0.33–0.46)
Gender, race
Female, white (n  457) 273 0.40 (0.35–0.44)
Male, white (n  707) 478 0.32 (0.28–0.35)
Male, non-white (n  145) 95 0.34 (0.26–0.42)
Female, non-white (n  56) 34 0.39 (0.26–0.51)
Marital status, race
Married, white (n  833) 532 0.36 (0.32–0.39)
Single, white (n  331) 219 0.33 (0.28–0.38)
Single, non-white (n  83) 50 0.40 (0.29–0.50)
Married, non-white (n  118) 79 0.32 (0.24–0.41)
a Married, married/other live-in relationship.
CI, confidence interval.
TABLE 2. Heterogeneity Testing Using Cox Proportional Hazards Regression Model for Overall Survival
Trial (No. of Death/No. of Patients)
Unadjusted Hazard Ratio
Gender (Male vs. Female RL)
Marital Status (Single vs.
Married RL)
Race (Non-White vs.
White RL)
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
9015 (22/23) 2.29 (0.66–7.91) 0.19 0.62 (0.25–1.55) 0.30 0.55 (0.12–2.45) 0.43
9103 (103/106) 1.42 (0.95–2.13) 0.08 1.65 (1.08–2.53) 0.02 1.07 (0.70–1.64) 0.76
9106 (62/73) 1.61 (0.96–2.72) 0.07 1.38 (0.80–2.38) 0.24 0.84 (0.38–1.84) 0.66
9204 arm 1 (69/74) 0.81 (0.47–1.38) 0.42 1.31 (0.74–2.32) 0.36 0.58 (0.27–1.28) 0.18
9204 arm 2 (71/78) 1.33 (0.83–2.15) 0.24 0.99 (0.56–1.76) 0.98 0.86 (0.47–1.58) 0.63
9205 (32/34) 1.16 (0.52–2.61) 0.71 0.83 (0.41–1.67) 0.59 1.20 (0.28–5.15) 0.81
9304 RT arm (53/55) 1.33 (0.75–2.37) 0.33 1.00 (0.57–1.73) 0.99 1.82 (0.85–3.91) 0.12
9311 (111/162) 1.53 (1.05–2.25) 0.03 1.05 (0.72–1.54) 0.79 1.35 (0.79–2.90) 0.27
9410 arm1 (164/170) 1.31 (0.95–1.80) 0.09 0.94 (0.66–1.34) 0.74 1.22 (0.78–1.89) 0.39
9410 arm2 (171/184) 0.99 (0.72–1.35) 0.93 0.74 (0.53–1.04) 0.08 0.66 (0.41–1.06) 0.09
9410 arm3 (167/183) 1.12 (0.81–1.56) 0.48 0.99 (0.71–1.39) 0.96 1.06 (0.69–1.63) 0.78
9801 (178/223) 1.26 (0.93–1.72) 0.14 1.03 (0.74–1.44) 0.86 1.14 (0.77–1.70) 0.51
2 TS  8.7 2 TS  12.1 2 TS  10.32
p  0.44 p  0.72 p  0.59
Pooled hazard ratioa 1.24 (1.09–1.41) — 1.01 (0.89–1.16) — 1.01 (0.84–1.20) —
b This is a pooled estimate.
CI, confidence interval; RL, reference level; TS, test statistic.
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in lung cancer. Men and women are diagnosed at approxi-
mately the same age. However, women seem to develop lung
cancer after considerably less exposure to tobacco smoke.35
The proportion of adenocarcinoma is also higher in women.
Hormonal factors have been implicated in the pathogenesis of
NSCLC. ER-mediated signaling promotes tumorigenesis in
response to estrogen binding or through transactivation of the
EGFR with further downstream activation of extracellular sig-
nal-regulated kinase.36–40 In vitro studies on various human
NSCLC cell lines have shown that the endogenous gene
expression profile in NSCLC is altered in response to estro-
gens and antiestrogens by the ER-.41 Estrogen therapy may
increase the risk of developing adenocarcinoma of the lung;
lower age at diagnosis and poorer survival have been noted in
women who received estrogens as a part of a hormonal replace-
ment therapy regimen.42,43
Lung cancer susceptibility because of smoking and nico-
tine metabolism also has gender-specific genetic differences.
Levels of aromatic/hydrophobic DNA adduct formation in re-
sponse to smoking is higher in females.44 DNA repair capacity
for tobacco carcinogen-induced DNA adduct formation is less in
women with a consequent higher rate of mutations.45 Cyto-
chrome P450 1A1 is an enzyme that bioactivates polycyclic
aromatic hydrocarbons, which in turn lead to DNA adduct
formation. Its levels are noted to be approximately 4-fold higher
in women, and it plays a significant role in DNA adduct
formation.46,47 Null phenotype of glutathione transferase M1, a
negative regulator of polycyclic aromatic hydrocarbons, is more
frequent in female lung cancer patients.47,48 K-ras mutations
were noted to be more common in adenocarcinomas in females
when compared with males.49 Mutations in the p53 tumor
suppressor gene are common in women in response to exposure
to tobacco smoke with a shift in the mutation spectrum in female
smokers.50–53 Gender differences in the murine double minute-2
gene, a negative regulator of p53, may be responsible for earlier
tumor development in women.54
TABLE 4. Comparison of Subgroups for Overall Survival
Pairwise Comparison Adjusted HRa 95% CI Pairwise Comparison Adjusted HRa 95% CI
Married,b white, male (RL) vs. single,
white, male
1.03 (0.85–1.26) Male, single (RL) vs.
female, married
0.85 (0.70–1.05)
Married, white, male (RL) vs. married,
non-white, male
1.05 (0.83–1.34) Male, single (RL) vs.
female, single
0.72 (0.58–0.89)
Single, white, male (RL) vs. single,
non-white, male
0.93 (0.64–1.36) Female, single (RL) vs.
female, married
1.14 (0.93–1.40)
Married, non-white, male (RL) vs.
single, non-white, male
0.72 (0.46–1.12) Female, single (RL) vs.
male, married
1.36 (1.14–1.62)
Married, white, female (RL) vs. single,
white, female
0.93 (0.74–1.16) Male, married (RL) vs.
female, married
0.86 (0.74–1.01)
Married, white, female (RL) vs.
married, non-white, female
1.32 (0.79–2.19) Male, white (RL) vs.
male, non-white
0.99 (0.81–1.20)
Single, white, female (RL) vs. single,
non-white, female
0.87 (0.56–1.35) Male, white (RL) vs.
female, non-white
0.80 (0.58–1.10)
Married, non-white, female (RL) vs.
single, non-white, female
0.43 (0.20–0.96) Male, white (RL) vs.
female, white
0.80 (0.70–0.92)
Married, white, female (RL) vs.
married, white, male
1.16 (0.99–1.38) Female, white (RL) vs.
female, non-white
1.00 (0.72–1.37)
Married, non-white female (RL) vs.
married, non-white, male
1.08 (0.61–1.90) Female, white (RL) vs.
male, non-white
1.23 (1.004–1.51)
Single, white, female (RL) vs. single,
white, male
1.49 (1.17–1.91) Male, non-white (RL) vs.
female, non-white
0.77 (0.54–1.10)
Single, non-white, female (RL) vs.
single, non-white, male
1.73 (0.99–3.04) Single, white (RL) vs.
single, non-white
0.92 (0.70–1.21)
Married, white, female (RL) vs. single,
white, male
1.25 (0.99–1.57) Single, white (RL) vs.
married, non-white
1.21 (0.95–1.53)
Married, non-white, female (RL) vs.
single, non-white, male
1.12 (0.57–2.21) Single, white (RL) vs.
married, white
1.07 (0.93–1.24)
Single, white, female (RL) vs. married,
white, male
1.31 (1.08–1.59) Married, white (RL) vs.
married, non-white
1.13 (0.91–1.40)
Single, non-white, female (RL) vs.
married, non-white, male
1.99 (1.20–3.31) Married, white (RL) vs.
single, non-white
0.88 (0.68–1.12)
Male, single (RL) vs. male, married 1.00 (0.84–1.19) Single, non-white (RL) vs.
married, non-white
1.51 (1.06–2.15)
a This is from stratified Cox-proportional hazard models (by STR) adjusted by all the following covariates: age (continuous), Karnofsky Performance Status (RL: 60–80), weight
loss in last 3 mo (RL: 5%), histology (RL: nonsquamous), stage (RL: stage I–II), lobar location (RL: all other than lower lobes), Biologically Effective Dose (outcomes) based
on actual dose/Fx (Gy), deviations of total dose received from total dose in protocol (RL: actual total dose is 95% of protocol total dose), and highest education level (RL: high
school/GED).
b Married, married/other live-in relationship.
RL, reference level; HR, hazard ratio; CI, confidence interval.
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We also examined the prognostic significance of marital
status. By using RTOG data, Konski et al.9 demonstrated that in
patients with head and neck cancers, unpartnered men were at a
significant survival disadvantage. This factor has also been
examined previously in lung cancer. Surveillance, Epidemiology
and End Results data analysis on 25,871 lung cancer patients
showed that partnered patients did significantly better than
single, separated, divorced, or widowed patients.55 A study
consisting of 15,882 male and 3,944 female lung cancer patients
identified in the Norwegian Cancer Registry showed that excess
all-cause mortality was highest in never-married men and wom-
en.56 Another Norwegian study also noted poorer survival in
divorced women.57 More recently, however, there has been
some evidence to the contrary. Jatoi et al.58 used data from
approximately 8000 patients enrolled in the Mayo Clinic Lung
Cancer Cohort. They did not find marital status to significantly
affect survival on univariate or multivariate analysis. Another
study from the Lung Cancer Database Project in Japan showed
no significant association between marital status and survival
when men and women were examined as a single group.59
However, on subgroup analysis, widowed men had a higher
mortality risk than married men. In our analysis, marital status
did not significantly predict for OS in lung cancer. Conversely,
subgroup analyses revealed that single white males had inferior
OS compared with married and single white females. Yet, both
married and single males had inferior outcomes when compared
with married females, underscoring the fact that gender was the
primary determinant of outcome. Overall, the suggestion of
Konski et al.9 of a disadvantage of unpartnered men found
support in the present data, but its expression was complex in the
context of simultaneous consideration of gender, marital status,
and race.
The impact of race and ethnicity on outcome in lung
cancer patients has also received considerable attention. In
this analysis, race did not significantly influence outcome,
although this might be due to a small number of nonwhite
patients to detect a significant difference. However, the
alarming increase in incidence and mortality from lung
cancer among the African American population must be
further investigated.
In conclusion, gender was the key prognostic factor
in lung cancer, with women having better OS. Marital status
and race did not significantly influence outcome. On sub-
group analysis, some combinations of marital status and race
TABLE 5. Review of Literature Outlining Publications Regarding Influence of Gender on Outcome
Study Total Male (%) Female (%) Stages Nature of Study
Median Survival
(mo) Os at 5 yr
Better outcome for women
O’Connell et al.18 378 70 30 III Single institution
(MSKCC)
M: 8.8
F: 12.4
Ferguson et al.a17 772 62 38 I–IIIB Retrospective M: 7.5 M: 10%b
F: 11.2 F: 18%
Albain et al.14 2531 67 33 “Extensive” 14 SWOG trials M: 4.8 M: 14%
F: 5.7 F: 19% at 1 yr
Paesmans et al.19 1052 90 10 I–IV ELCWP trials FM FM
Werner-Wasik et al.23 1999 72 28 I–IV Prospective data from
RTOG trials
M: 9.9
F: 11.4
Radzikowska et al.20 20561 86 14 I–IV Registry data M: 9.6b M: 18%b
F: 11.3 F: 23% at 2 yr
Chatkin et al.16 109 70 30 I Retrospective M: 32.3 M: 46.4%
F: 63.9 F: 85.5%
Visbal et al.21 4618 59 41 I–IV Single institution M: 12 M: 15%
F: 16.8 F: 19%
Cerfolio et al.15 1085 62 38 I–III Prospective cohort- single
institution
NA M: 50%
F: 60%
Wakelee et al.22 1157 63 37 IIIB–IV ECOG E1594 randomized
trial
M: 7.3 M: 5%
F: 9.2 F: 7% at 3 yr
No gender difference
Caldarella et al.25 2262 79 21 I–IV Registry data M: 6.5b M: 10.5%
F: 6.5 F: 9.4%
Foegle et al.26 1738 89 11 I–IV Registry data M: 10.5 M: 15.3%
F: 9.9 F: 17.1%
Belani et al.24 1218 73 27 III–IV TAX 326 trial M: 9.2–11 M: 13%–18%
F: 10.8–12.2 F: 18%–26% at 2 yr
a Not reported in manuscript. Estimated from figure presented.
b Also included small cell lung cancers patients (18.3%).
MSKCC, Memorial Sloan-Kettering Cancer Center; SWOG, South West Oncology Group; ECOG, Eastern Cooperative Oncology Group; ELCWP, European Lung Cancer
Working Party; RTOG, Radiation Therapy Oncology Group; M, male; F, female.
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did have an inferior outcome; however, the interactions were
complex. This observation from a large RTOG cohort
underscores the need to design future trials and studies to
better understand and tailor regimens to address these
gender differences.
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